Update from CredibleMeds

We have received the following from CredibleMeds. Subscribe to their newsletter if you would like to receive regular updates from them too.

June 26, 2023

Re: Changes to the QTdrugs List and List of Drugs to Avoid in cLQTS

Dear CredibleMeds Registrants:

AZCERT’s Scientific Review Committee has found substantial evidence that Pacritinib (anticancer), Vernakalant (antiarrhythmic) and Fexinidazole (antiparasitic) are associated with the development of QT prolongation but lack convincing evidence of torsades de pointes (TdP).  Therefore, these drugs have been added to the Possible Risk of TdP category (PR) and the List of Drugs to Avoid in patients with Congenital Long QT Syndrome (DTA List).  

As demonstrated by these revisions, the QTdrugs list is dynamic and changes regularly.  To perform a quick search of the Lists we recommend using the CredibleMeds website and the smartphone app (Apple or Android).

Best wishes,

Ray Woosley and the Scientific Review Committee for AZCERT

Will Heise, MD
Klaus Romero, MD
Tyler Gallo, PharmD
R. David Woosley, MPH
Joseph Lambson, PharmD

More to explorer

myheart hard copy newsletter-2023

Members who subscribed to the myheart hard copy newsletter should have now received it. Read the online version here. Subscribe to myheart mailings here.

624 Reasons Why by Joe McEwan

My name is Joe, and I suppose you could say I’m your fairly average 23-year-old man. I graduated from university with a

WhatsApp
Facebook
Twitter
Reddit
Email
Skip to content